Related Experiment Video
Updated: Jun 14, 2025
05:23
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
294
Helicobacter pylori CAs inhibition.
Bianca Laura Bernardoni1, Concettina La Motta1, Simone Carradori2
1Department of Pharmacy, University of Pisa, Pisa, Italy.
The Enzymes
|September 2, 2024
Summary
Helicobacter pylori infections pose a global health risk due to drug resistance. Targeting Hp carbonic anhydrases (HpαCA and HpβCA) offers a promising strategy for developing new antibacterial agents.
Area of Science:
- Microbiology and Infectious Diseases
- Biochemistry and Enzymology
- Drug Discovery and Pharmacology
Background:
- Helicobacter pylori (Hp) infections are a major global health concern, linked to severe conditions like gastric cancer and peptic ulcers.
- Increasing antimicrobial resistance necessitates novel therapeutic strategies against Hp.
- Hp carbonic anhydrases (HpαCA and HpβCA) are vital for pathogen survival and represent promising drug targets.
Purpose of the Study:
- To explore the potential of Hp carbonic anhydrases (HpαCA and HpβCA) as therapeutic targets for combating H. pylori infections.
- To investigate the druggability and essential role of these enzymes in H. pylori pathogenesis.
- To lay the groundwork for developing new antibacterial agents by characterizing these enzymes and their inhibitors.
Main Methods:
- Isolation and characterization of HpαCA and HpβCA isoenzymes.
- Kinetic profiling of the purified carbonic anhydrase enzymes.
- Screening of inhibitor series against Hp carbonic anhydrases.
Main Results:
- The study successfully isolated and characterized HpαCA and HpβCA.
- Kinetic properties of both isoenzymes were analyzed.
- Initial investigations into inhibitor series targeting these enzymes were conducted.
Conclusions:
- Hp carbonic anhydrases are validated as highly druggable targets with a crucial role in H. pylori survival.
- The characterization of HpαCA and HpβCA provides a foundation for rational drug design against H. pylori.
- Developing inhibitors for these enzymes holds significant potential for new anti-H. pylori therapies to address drug resistance.
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
335
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
335
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
100
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
100
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
545
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
545
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
358
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
358
01:26Peptic Ulcer Disease IV: Management
78
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
78
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
410
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
410